Nykode Therapeutics AS (FRA:5VB)

Nykode Therapeutics AS Statistics

Total Valuation

FRA:5VB has a market cap or net worth of EUR 61.02 million. The enterprise value is 9.24 million.

Market Cap	61.02M
Enterprise Value	9.24M

Important Dates

The last earnings date was Monday, November 24, 2025.

Earnings Date	Nov 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	326.55M
Shares Outstanding	n/a
Shares Change (YoY)	-22.32%
Shares Change (QoQ)	+12.08%
Owned by Insiders (%)	15.08%
Owned by Institutions (%)	33.62%
Float	159.52M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.75
PB Ratio	0.72
P/TBV Ratio	0.72
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-0.99
EV / Sales	1.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.30

Financial Position

The company has a current ratio of 17.14, with a Debt / Equity ratio of 0.03.

Current Ratio	17.14
Quick Ratio	17.14
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-191.94

Financial Efficiency

Return on equity (ROE) is -9.10% and return on invested capital (ROIC) is -13.28%.

Return on Equity (ROE)	-9.10%
Return on Assets (ROA)	-12.08%
Return on Invested Capital (ROIC)	-13.28%
Return on Capital Employed (ROCE)	-26.02%
Revenue Per Employee	100,984
Profits Per Employee	-151,242
Employee Count	136
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	-4.81M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +3.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+3.84%
50-Day Moving Average	0.14
200-Day Moving Average	0.14
Relative Strength Index (RSI)	49.54
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:5VB had revenue of EUR 6.26 million and -9.38 million in losses. Loss per share was -0.03.

Revenue	6.26M
Gross Profit	6.26M
Operating Income	-22.58M
Pretax Income	-14.18M
Net Income	-9.38M
EBITDA	-21.95M
EBIT	-22.58M
Loss Per Share	-0.03

Balance Sheet

The company has 54.49 million in cash and 2.47 million in debt, giving a net cash position of 52.02 million.

Cash & Cash Equivalents	54.49M
Total Debt	2.47M
Net Cash	52.02M
Net Cash Per Share	n/a
Equity (Book Value)	84.59M
Book Value Per Share	0.26
Working Capital	53.72M

Cash Flow

In the last 12 months, operating cash flow was -30.42 million and capital expenditures -74,150, giving a free cash flow of -30.49 million.

Operating Cash Flow	-30.42M
Capital Expenditures	-74,150
Free Cash Flow	-30.49M
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of -360.58% and -149.77%.

Gross Margin	100.00%
Operating Margin	-360.58%
Pretax Margin	-226.52%
Profit Margin	-149.77%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:5VB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	22.32%
Shareholder Yield	22.32%
Earnings Yield	-15.37%
FCF Yield	-49.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:5VB has an Altman Z-Score of 6.95 and a Piotroski F-Score of 2.

Altman Z-Score	6.95
Piotroski F-Score	2